(Q45732561)

15 December 2017

title

Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression (English)

1 reference

15 December 2017

6

Robert Colebunders

1 reference

15 December 2017

2

Ineke Stolte

1 reference

15 December 2017

9

Roel A Coutinho

1 reference

15 December 2017

3

Miranda W Langendam

1 reference

15 December 2017

author name string

Catharina E A Lindenburg

1

1 reference

15 December 2017

Frank Miedema

4

1 reference

15 December 2017

Ian G Williams

5

1 reference

15 December 2017

Jonathan N Weber

7

1 reference

15 December 2017

Martin Fisher

8

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

15 December 2017

1 reference

15 December 2017

volume

20

1 reference

15 December 2017

issue

17-18

1 reference

15 December 2017

page(s)

2343-2347

1 reference

Prospects for the control of AIDS by immunizing seropositive individuals

15 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

The expression of hybrid HIV:Ty virus-like particles in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Expanded European AIDS case definition

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Active Immunization of Patients with HIV Infection: A Study of the Effect of VaxSyn, a Recombinant HIV Envelope Subunit Vaccine, on Progression of Immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

The effectiveness of interventions on incubation of AIDS as measured by secular increases within a population

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900102-0

7 January 2021

10.1016/S0264-410X(02)00102-0

Identifiers

DOI

1 reference

15 December 2017

1 reference